The tumor necrosis factor superfamily in heart failure

Future Cardiology

Volumn 2, Issue 1, 2006, Pages 101-111

  Ueland, T ^a   Aukrust, P ^b   Damas, J K ^b   Gullestad, L ^b   Yndestad, A ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cytokine; Heart failure; Immune system; Inflammation; Tumor necrosis factor

Indexed keywords

APRIL PROTEIN; CD40 ANTIGEN; CD40 LIGAND; CYTOKINE; ETANERCEPT; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PENTOXIFYLLINE; STRESS ACTIVATED PROTEIN KINASE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG FATALITY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HEART FAILURE; HEART MUSCLE CELL; HUMAN; HYPERTROPHY; IMMUNE SYSTEM; INFLAMMATION; MYOCARDIAL DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 33646539111     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.1.101     Document Type: Article

References (96)

1. Jessup M, Brozena S: Heart failure. N. Engl. J. Med. 348, 2007-2018 (2003).
2. Mann DL, Deswal A. Bozkurt B, Torre-Amione G: New therapeutics for chronic heart failure. Ann. Rev. Med. 53, 59-74 (2002).
3. Levinue B, Kalman J, Mayer L, Fillit HM. Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236-241 (1990).
4. Mann DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91, 988-998 (2002).
5. Nishigaki K, Minatoguchi S, Seishima M et al.: Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J. Am. Coll. Cardiol. 29, 1214-1220 (1997).
6. Yamaguchi S, Yamaoka M, Okuyama M et al.: Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. A. J. Cardiol. 83, 1500-1503, A8 (1999).
7. Badorff C, Ruetten H, Mueller S et al.: Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J. Clin. Invest. 109, 373-381 (2002).
8. Ware CF: The TNF superfamily. Cytokine Growth Factor Rev. 14, 181-184 (2003).
9. Aggarwal BB: Signalling pathways of the TNF superfamily: a double-edged sword. Nature Rev. Immunol. 3, 745-756 (2003).
10. Dempsey PW, Doyle SE, He JQ. Cheng G: The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 14, 193-209 (2003).
11. Chung JY, Park YC, Ye H, Wu H: All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J. Cell. Sci. 115, 679-688 (2002).
12. Gaur U, Aggarwal BB: Regulation of proliferation. survival and apoptosis by members of the TNF superfamily. Biochem. Pharmacol. 66, 1403-1408 (2003).
13. Bonizzi G, Karin M: The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25, 280-288 (2004).
14. Takayanagi. H, Ogasawara K, Hida S, Chiba T et al: T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408, 600-605 (2000).
15. Mach F, Schonbeck U. Sukhova GK et al.: Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl Acad. Sci. USA 94, 1931-1936 (1997).
16. Watts TH: TNF/TNFR family members in costimulation of T cell responses. Ann. Rev. Immunol. 23, 23-68 (2005).
17. Aukrust P, Liabakk NB, Muller F, Lien E, Espevik T, Froland SS: Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus Type 1 infection-correlations to clinical, immunologic, and virologic parameters. J. Infect. Dis. 169, 420-424 (1994).
18. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G: Expression and function of OX40 ligand on human dendritic cells. J. Immunol. 159, 3838-3848 (1997).
19. Futagawa T, Akiba H, Kodama T et al.: Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 14, 275-286 (2002).
20. + T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. J. Immunol. 170, 1797-1805 (2003).
21. Anderson DM, Maraskovsky E, Billingsley WL et al.: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179 (1997).
22. Subauste CS: CD154 and type-1 cytokine response: from hyper IgM syndrome to human immunodeficiency virus infection. J. Infect. Dis. 185,(Suppl. 1) S83-S89 (2002).
23. Takayanagi H, Iizuka H, Juji T et al.: Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 43, 259-269 (2000).
24. Wang J, Anders RA, Wang Y et al.: The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. J. Immunol. 174, 8173-8182 (2005).
25. Liu ZG, Hsu H, Goeddel DV. Karin M: Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87, 565-576 (1996).
26. + T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J. Exp. Med. 185. 55-64 (1997).
27. Yndestad A, Damas JK, Geir EH et al.: Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc. Res. 54, 175-182 (2002).
28. Torre-Amione G, Kapadia S, Lee J et al.: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93, 704-711 (1996).
29. Jeremias I, Kupatt C, Martin-Villalba A et al.: Involvement of CD95/Apo1/ Fas in cell death after myocardial ischemia. Circulation 102, 915-920 (2000).
30. Madry C, Laabi Y. Callebaut I et al.: The characterization of murine BCAM gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int. Immunol. 10, 1693-1702 (1998).
31. Kwon BS, Tan KB, Ni J et al.: A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J. Biol. Chem. 272, 14272-14276 (1997).
32. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES: Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 272, 25417-25420 (1997).
33. Pan G, O'Rourke K, Chinnaiyan AM et al.: The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113 (1997).
34. Pan G, Ni J, Yu G, Wei YF, Dixit VM: TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL. signalling. FEBS Lett. 424, 41-45 (1998).
35. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL: Science 277, 815-818 (1997).
36. Ueland T. Yndestad A. Oie E et al.: Dysregulated osteoprotegerin/RANK ligand/RANK aids in clinical and experimental heart failure. Circulation 111, 2461-2468 (2005).
37. Darnay BG, Aggarwal BB: Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors. Ann. Rheum. Dis. 58,(Suppl. 1) I2-I13 (1999).
38. Kang PM, Izumo S: Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases. Tiends Mol. Med. 9, 177-182 (2003).
39. Baines CP, Molkentin JD: STRESS signaling pathways that modulate cardiac myocyte apoptosis. J. Mol. Cell Cardiol. 38 47-62 (2005).
40. Linke A, Recchia F, Zhang X, Hintze TH: Acute and chronic endothelial dysfunction: implications for the development of heart failure. Heart Fail Rev. 8, 87-97 (2003).
41. Yndestad A, Holm AM, Muller F et al: Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc. Res. 60, 141-146 (2003).
42. Varda-Bloom N, Leor J, Ohad DG et al: Cytotoxic T lymphocytes are activated following myocardial infarction and can recognize and kill healthy myocytes in vitro. J. Mol. Cell Cardiol. 32, 2141-2149 (2000).
43. Nitobe J. Yamaguchi S, Okuyama M et al.: Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes. Cardiovasc. Res. 57 119-128 (2003).
44. Yaniv G, Shilkrut M, Lotan R, Berke G, Larisch S, Binah O: Hypoxia predisposes neonatal rat ventricular myocytes to apoptosis induced by activation of the Fas (CD95/Apo-1) receptor: Fas activation and apoptosis in hypoxic myocytes. Cardiovasc. Res. 54, 611-623 (2002).
45. Lee P. Sata M, Lefer DJ, Factor SM, Walsh K, Kitsis RN: Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo. Am. J. Physiol. Heart Circ. Physiol. 284, H456-H463 (2003).
46. Almasan A, Ashkenazi A: Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14, 337-348 (2003).
47. Baetu TM, Hiscott J: On the TRAIL to apoptosis. Cytokine Growth Factor Rev. 13, 199-207 (2002).
48. Sivasubramanian N, Coker ML, Kurrelmeyer KM et al: Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 104, 826-831 (2001).
49. Nelson DP, Setser E, Hall DG et al: Proinflammatory consequences of transgenic Fas ligand expression in the heart. J. Clin. Invest. 105, 1199-1208 (2000).
50. Wong SC, Fukuchi M, Melnyk P, Rodger I, Giaid A: Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation 98, 100-103 (1998).
51. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A: Activation of NF-kappaB is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl Acad. Sci. USA 98, 6668-6673 (2001).
52. Lee WH, Kim SH, Lee Y et al: Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler. Thromb. Vasc. Biol. 21, 2004-2010 (2001).
53. Yurovsky VV: Tumor necrosis factor-related apoptosis-inducing ligand enhances collagen production by human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 28, 225-231 (2003).
54. Flesch M, Hoper A, Dell'Italia L et al: Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 108, 598-604 (2003).
55. Peng J, Gurantz D, Tran V, Cowling RT, Greenberg BH: Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circ. Res. 91, 1119-1126 (2002).
56. Gulick T, Chung MK, Pieper SJ, Lange LG. Schreiner GF: Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc. Natl Acad. Sci. USA 86, 6753-6757 (1989).
57. Sharov VG, Todor A, Suzuki G. Morita H, Tanhehco EJ, Sabbah HN: Hypoxia, angiotensin-II, and norepinephrine mediated apoptosis is stimulus specific in canine failed cardiomyocytes: a role for p38 MAPK, Fas-L and cyclin D1. Eur J. Heart Fail, 5, 121-129 (2003).
58. Mackay F, Ambrose C: The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev. 14, 311-324 (2003).
59. Croft M: Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. 14, 265-273 (2003).
60. Hollenbaugh D, Grosmaire LS, Kullas CD et al.: The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J. 11, 4313-4321 (1992).
61. Grewal IS, Flavell RA: The CD40 ligand. At the center of the immune universe? Immunol. Res. 16, 59-70 (1997).
62. Henn V. Slupsky JR, Grafe M et al.: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591-594 (1998).
63. May AE, Kalsch T, Massberg S, Herouy Y. Schmidt R, Gawaz M: Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 106, 2111-2117 (2002).
64. Buhlmann JE, Noelle RJ: Therapeutic potential for blockade of the CD40 ligand, gp39. J. Clin. Immunol. 16, 83-89 (1996).
65. Aukrust P, Muller F, Ueland T et al.: Enhanced levels of soluble and membrane-bound CD40 ligand In patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100, 614-620 (1999).
66. Garlichs CD, Eskafi S, Raaz D et al.: Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 86, 649-655 (2001).
67. Lee Y, Lee WH, Lee SC et al.: CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology 92, 11-16 (1999).
68. Peng DQ, Zhao SP, Li YF, Li J, Zhou HN: Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin. Chim. Acta 319, 19-26 (2002).
69. Heeschen C, Dimmeler S. Hamm CW et al.: Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 348, 1104-1111 (2003).
70. Yan J, Wu Z, Huang Z. Li L, Zhong R, Kong X: Clinical implications of increased expression of CD40L in patients with acute coronary syndromes. Chin. Med. J. 115, 491-493 (2002).
71. Ueland T, Aukrust P, Yndestad A et al: Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J. 26, 1101-1107 (2005).
72. Anand SX, Viles-Gonzalez JF, Badimon JJ. Cavusoglu E, Marmur JD: Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb. Haemost. 90, 377-384 (2003).
73. Stumpf C, Lehner C, Eskafi S et al.: Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur. J. Heart Fail. 5, 629-637 (2003).
74. Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS: CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl Acad. Sci. USA 92, 4342-4346 (1995).
75. Henn V, Slupsky JR, Grafe M et al: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591-594 (1998).
76. Seko Y, Takahashi N, Ishiyama S et al: Expression of costimulatory molecules B7-1, B7-2, and CD40 in the heart of patients with acute myocarditis and dilated cardiomyopathy. Circulation 97, 637-639 (1998).
77. Seko Y, Takahashi N, Oshima H et al.: Expression of tumour necrosis factor (TNF) receptor/ligand superfamily co-stimulatory molecules CD40, CD30L. CD27L, and OX40L in murine hearts with chronic ongoing myocarditis caused by coxsackie virus B3. J. Pathol. 188, 423-430 (1999).
78. Yndestad A, Holm AM. Müller F et al. P: Enhanced expression of inflammatory cytokines and activation markers in T cells during chronic heart failure. Cardiovasc. Res. In press (2003).
79. Hofbauer LC, Heufelder AE: The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J. Clin. Endocrinol. Metab. 85, 2355-2363 (2000).
80. Walsh MC. Choi Y: Biology of the TRANCE axis. Cytokine Growth Factor Rev. 14, 251-263 (2003).
81. Afanasyeva M, Georgakopoulos D, Belardi DF et al.: Quantitative analysis of myocardial inflammation by flow cytometry in murine autoimmune myocarditis: correlation with cardiac function. Am. J. Pathol. 164, 807-815 (2004).
82. Afanasyeva M, Georgakopoulos D, Rose NR: Autoimmune myocarditis: cellular mediators of cardiac dysfunction. Autoimmun. Rev. 3, 476-486 (2004).
83. Yu Q. Watson RR, Marchalonis JJ, Larson DF: A role for T lymphocytes in mediating cardiac diastolic function. Am. J. Physiol. Heart Circ. Physiol. 289, H643-H651 (2005).
84. Bozkurt B, Torre-Amione G, Warren MS et al.: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103, 1044-1047 (2001).
85. Mann DL, McMurray JJ, Packer M et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594-1602 (2004).
86. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133-3140 (2003).
87. Kadokami T. McTiernan CF, Kubota T et al.: Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. Am. J. Physiol. Head Circ. Physiol. 280, H2281-H2291 (2001).
88. Lugering A, Schmidt M, Lugering N, Pauels HG. Domschke W, Kucharzik T: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121, 1145-1157 (2001).
89. Kunisada K, Tone E, Fujio, Y, Matsui H, Yamauchi-Takihara K, Kishimoto T: Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 98, 346-352 (1998).
90. Meldrum DR: Tumor necrosis factor in the heart. Am. J. Physiol. 274, R577-R595 (1998).
91. Hirota H, Chen J, Betz UA et al: Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97, 189-198 (1999).
92. Li YY, Kadokami T, Wang P, McTiernan CF, Feldman AM: MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am. J. Physiol. Heart Circ. Physiol. 282, H983-H989 (2002).
93. Abraham E: Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med. 25, 556-566 (1999).
94. Gullestad L. Aass H, Fjeld JG et al: Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103, 220-225 (2001).
95. Felix SB, Staudt A, Landsberger M et al: Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J. Am. Coll. Cardiol. 39, 646-652 (2002).
96. Schonbeck U. Libby P: Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109. II18-II26 (2004).